Three drug classes have been used to inhibit H+/K+-ATPases. H2-receptor antagonists, like cimetidine (Tagamet), inhibit the signaling pathway that leads to activation of the ATPase. This type of inhibitor is effective in treating ulcers but does not prevent them from forming, and patients develop tolerance to them after about one week, leading to a 50% reduction in efficacy.
Three drug categories have been utilized to inhibit H+/K+-ATPases. H2-receptor antagonists, such as cimetidine (Tagamet), interfere with the pathway that activates ATPase. These inhibitors are effective in treating ulcers but do not prevent their formation and can cause patient tolerance within a week, leading to a 50% reduction in effectiveness.